Fragment Linking Strategies for Structure-Based Drug Design
- 22 October 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (20), 11420-11435
- https://doi.org/10.1021/acs.jmedchem.0c00242
Abstract
Fragment-based drug discovery is a strategy widely used in both academia and pharmaceutical companies to generate small-molecule protein inhibitors and drug candidates. Among the approaches reported in the literature (growing, linking, and merging), the linking approach theoretically offers the opportunity to rapidly gain in binding energy. Nevertheless, this approach is poorly represented when considering the compounds currently in clinical trials. Here, we report an exhaustive view of the cases published so far in the literature, together with the methods used to identify the two initial fragments either simultaneously or successively. We review the different types of linkers published and discuss how these linkers are designed to obtain the lead compound. Mixing merging and linking methods, where the linker is duplicated from a known inhibitor, appears as an interesting strategy. To reach superadditivity, we propose to grow one of the fragments in order to minimize the distance between the two binders and then link the resulting compounds using flexible alkyl-derived linkers.Funding Information
- Agence Nationale de la Recherche
- Ligue Contre le Cancer
- Centre National de la Recherche Scientifique (CNRS80Prime)
This publication has 80 references indexed in Scilit:
- A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDAMedChemComm, 2019
- Fragment-to-Lead Medicinal Chemistry Publications in 2017Journal of Medicinal Chemistry, 2018
- Twenty years on: the impact of fragments on drug discoveryNature Reviews Drug Discovery, 2016
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Structural biology in fragment-based drug designCurrent Opinion in Structural Biology, 2010
- From fragment to clinical candidate—a historical perspectiveDrug Discovery Today, 2009
- A decade of fragment-based drug design: strategic advances and lessons learnedNature Reviews Drug Discovery, 2007
- Fragment-based lead discoveryNature Reviews Drug Discovery, 2004
- A ‘Rule of Three’ for fragment-based lead discovery?Drug Discovery Today, 2003